Toxins 2013, 5(7), 1244-1260; doi:10.3390/toxins5071244
Review

Mini-Review: Novel Therapeutic Strategies to Blunt Actions of Pneumolysin in the Lungs

Received: 31 May 2013; in revised form: 25 June 2013 / Accepted: 27 June 2013 / Published: 15 July 2013
(This article belongs to the Special Issue Pore-Forming Toxins)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Severe pneumonia is the main single cause of death worldwide in children under five years of age. The main etiological agent of pneumonia is the G+ bacterium Streptococcus pneumoniae, which accounts for up to 45% of all cases. Intriguingly, patients can still die days after commencing antibiotic treatment due to the development of permeability edema, although the pathogen was successfully cleared from their lungs. This condition is characterized by a dramatically impaired alveolar epithelial-capillary barrier function and a dysfunction of the sodium transporters required for edema reabsorption, including the apically expressed epithelial sodium channel (ENaC) and the basolaterally expressed sodium potassium pump (Na+-K+-ATPase). The main agent inducing this edema formation is the virulence factor pneumolysin, a cholesterol-binding pore-forming toxin, released in the alveolar compartment of the lungs when pneumococci are being lysed by antibiotic treatment or upon autolysis. Sub-lytic concentrations of pneumolysin can cause endothelial barrier dysfunction and can impair ENaC-mediated sodium uptake in type II alveolar epithelial cells. These events significantly contribute to the formation of permeability edema, for which currently no standard therapy is available. This review focuses on discussing some recent developments in the search for the novel therapeutic agents able to improve lung function despite the presence of pore-forming toxins. Such treatments could reduce the potentially lethal complications occurring after antibiotic treatment of patients with severe pneumonia.
Keywords: pneumolysin; permeability edema; TNF; Growth Hormone-Releasing Hormone
PDF Full-text Download PDF Full-Text [1135 KB, uploaded 15 July 2013 09:52 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Lucas, R.; Czikora, I.; Sridhar, S.; Zemskov, E.; Gorshkov, B.; Siddaramappa, U.; Oseghale, A.; Lawson, J.; Verin, A.; Rick, F.G.; Block, N.L.; Pillich, H.; Romero, M.; Leustik, M.; Schally, A.V.; Chakraborty, T. Mini-Review: Novel Therapeutic Strategies to Blunt Actions of Pneumolysin in the Lungs. Toxins 2013, 5, 1244-1260.

AMA Style

Lucas R, Czikora I, Sridhar S, Zemskov E, Gorshkov B, Siddaramappa U, Oseghale A, Lawson J, Verin A, Rick FG, Block NL, Pillich H, Romero M, Leustik M, Schally AV, Chakraborty T. Mini-Review: Novel Therapeutic Strategies to Blunt Actions of Pneumolysin in the Lungs. Toxins. 2013; 5(7):1244-1260.

Chicago/Turabian Style

Lucas, Rudolf; Czikora, Istvan; Sridhar, Supriya; Zemskov, Evgeny; Gorshkov, Boris; Siddaramappa, Umapathy; Oseghale, Aluya; Lawson, Jonathan; Verin, Alexander; Rick, Ferenc G.; Block, Norman L.; Pillich, Helena; Romero, Maritza; Leustik, Martin; Schally, Andrew V.; Chakraborty, Trinad. 2013. "Mini-Review: Novel Therapeutic Strategies to Blunt Actions of Pneumolysin in the Lungs." Toxins 5, no. 7: 1244-1260.

Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert